Indications And Dose
Helicobacter pylori eradication [in combination with other drugs (see Helicobacter pylori infection p. 89)] ▶BY MOUTH ▶Adult: 20–40 mg twice daily for 7 days for first- and second-line eradication therapy; 10 days for third-line eradication therapy Benign gastric ulceration ▶BY MOUTH ▶Adult: 20 mg once daily for 8 weeks, increased if necessary to 40 mg once daily, in severe or recurrent cases Duodenal ulceration ▶BY MOUTH ▶Adult: 20 mg once daily for 4 weeks, increased if necessary to 40 mg once daily, in severe or recurrent cases Prevention of relapse in gastric ulcer ▶BY MOUTH ▶Adult: 20 mg once daily, increased if necessary to 40 mg once daily Prevention of relapse in duodenal ulcer ▶BY MOUTH ▶Adult: 20 mg once daily, dose may range between 10–40 mg daily NSAID-associated duodenal ulcer | NSAID-associated gastric ulcer | NSAID-associated gastroduodenal erosions ▶BY MOUTH Gastro-intestinal system ▶Adult: 20 mg once daily for 4 weeks, continued for a further 4 weeks if not fully healed Prophylaxis in patients with a history of NSAID-associated duodenal ulcer who require continued NSAID treatment | Prophylaxis in patients with a history of NSAID- associated gastric ulcer who require continued NSAID treatment | Prophylaxis in patients with a history of NSAID-associated gastroduodenal lesions who require continued NSAID treatment | Prophylaxis in patients with a history of NSAID-associated dyspeptic symptoms who require continued NSAID treatment ▶BY MOUTH ▶Adult: 20 mg once daily Zollinger–Ellison syndrome ▶BY MOUTH ▶Adult: Initially 60 mg once daily; usual dose 20–120 mg daily, total daily doses greater than 80 mg should be given in 2 divided doses ▶BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION ▶Adult: Initially 60 mg once daily, adjusted according to response, total daily doses greater than 60 mg should be given in 2 divided doses, injection to be given over 5 minutes, infusion to be given over 20–30 minutes Gastro-oesophageal reflux disease ▶BY MOUTH ▶Adult: 20 mg once daily for 4 or 8 weeks Severe oesophagitis ▶BY MOUTH ▶Adult: 40 mg once daily for 8 weeks, continue as maintenance treatment if appropriate Severe oesophagitis, refractory to initial treatment ▶BY MOUTH ▶Adult: 40 mg twice daily Acid reflux disease (long-term management) ▶BY MOUTH ▶Adult: 10 mg once daily, increased to 20 mg once daily, dose only increased if symptoms return Functional dyspepsia ▶BY MOUTH ▶Adult: 10 mg once daily for 4 weeks Uninvestigated dyspepsia ▶BY MOUTH ▶Adult: 20 mg once daily for 4 weeks Treatment and prevention of benign gastric ulcers | Treatment and prevention of duodenal ulcers | Treatment and prevention of NSAID-associated ulcers | Treatment and prevention of gastro-oesophageal reflux disease ▶BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION ▶Adult: 40 mg once daily until oral administration possible, injection to be given over 5 minutes, infusion to be given over 20–30 minutes Major peptic ulcer bleeding (following endoscopic treatment) ▶INITIALLY BY INTRAVENOUS INFUSION ▶Adult: Initially 80 mg, to be given over 40–60 minutes, then (by continuous intravenous infusion) 8 mg/hour for 72 hours, subsequent dose then changed to oral therapy l UNLICENSED USE ▶With oral use g Duration of treatment for gastro- oesophageal reflux disease differs from product literature and adheres to national guidelines. h See Gastro- oesophageal reflux disease p. 88 for further information. Omeprazole may be used as detailed below, although these situations are considered outside the scope of its licence: Gastro-intestinal system . g treatment of severe oesophagitis, refractory to initial treatment, h see Gastro-oesophageal reflux disease p. 88 for further information; . g treatment of functional and uninvestigated dyspepsia, h see Dyspepsia p. 72 for further information; . treatment of major peptic ulcer bleeding (following endoscopic treatment).
Source pages 107, 108